Key Takeaways
- Profusa shares climbed 95.6% during pre-market hours on August 18 following the company’s third reverse stock split this year
- A 1-for-4 reverse consolidation became effective August 17, reducing outstanding shares from approximately 2.42 million down to around 605,726
- The exceptionally low share count means minimal trading volume can trigger significant percentage movements
- The company holds an option agreement to purchase G3 Vision Labs and has signed a letter of intent regarding the PanOmics diagnostics technology
- Market indices declined during the session, with the Nasdaq falling 1.3%, confirming this as an isolated, company-specific movement
Shares of Profusa finished Monday’s session at $4.53, representing a 27% gain, before climbing an additional 77% in extended trading to reach $8.02. During Tuesday’s pre-market session, the stock continued its ascent with a 95.6% surge, nearly doubling from Monday’s closing price.
Profusa, Inc. Common Stock, PFSA
The catalyst appears largely technical in nature. The company implemented a 1-for-4 reverse stock consolidation that took effect at 12:01 a.m. Eastern Time on August 17, marking the third such action in 2026. This follows a previous 1-for-25 reverse split that concluded on July 7.
This consolidation decreased the share count from 2,422,906 down to roughly 605,726. A fresh CUSIP identifier was issued, with Tuesday’s pre-market representing the initial trading session where participants fully incorporated the revised capital structure.
With such a limited number of shares in circulation, substantial price movements require minimal capital. Even relatively small purchase orders generate oversized percentage gains, typically drawing short-term momentum traders seeking rapid profits.
Acquisition Plans Support Speculative Interest
Apart from the split-related mechanics, Profusa has been developing a corporate development narrative that maintains speculative trader attention. In early August, the firm entered into an option arrangement to purchase G3 Vision Labs, which operates as a commercial-stage diagnostics enterprise.
Additionally, there’s an outstanding letter of intent concerning the PanOmics multi-omics diagnostics technology. While neither transaction has reached completion, these M&A developments provide traders with fundamental storylines beyond simple reverse split dynamics.
A postponed quarterly regulatory submission, announced on August 14, also attracted additional market participant attention in the days preceding the price movement. While filing delays don’t necessarily signal problems, they frequently generate heightened scrutiny.
Broader Market Conditions Provide No Support
The general equity market environment provided zero assistance for this rally. The Nasdaq declined 1.3% while the S&P 500 dropped 0.5% during the same trading day. This confirms the movement as entirely company-specific.
Profusa specializes in continuous biochemistry monitoring technologies, including its Lumee Oxygen and Lumee Glucose monitoring platforms. No industry-wide developments in digital healthcare or biointegrated sensor technology emerged to justify the price surge.
The organization released no quarterly results nor disclosed any significant revenue-related announcement. The dramatic price action resulted from the convergence of an exceptionally small float, reverse split mechanics, and active speculative trading.
PFSA finished Monday’s regular session at $4.53 before advancing to $8.02 during after-hours trading, representing a 77% session gain, with pre-market activity driving prices even higher.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
